| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |